Levetiracetam Sandoz (Levetiracetam)

Levetiracetam exerts its antiepileptic effect by binding to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This binding modulates vesicle exocytosis, decreasing neuronal excitability and limiting the propagation of abnormal electrical activity that underlies seizures. The mechanism is distinct from many other anticonvulsants, offering an additional therapeutic option.

The appropriate dose of Levetiracetam Sandoz is determined individually by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage regimens may vary, and the medication should only be administered according to the specific instructions provided in the prescription and product labeling.

Safety data for levetiracetam in pregnancy are limited, and the drug is classified as pregnancy category unknown. Clinicians must weigh potential benefits against possible risks to the fetus. Breastfeeding mothers should consult their healthcare provider, as levetiracetam can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Compared with older agents such as carbamazepine or phenytoin, levetiracetam has a relatively favorable drug‑interaction profile and does not require routine therapeutic drug monitoring. Its distinct SV2A‑targeted mechanism can be advantageous for patients who have not responded to sodium‑channel blockers. However, individual response varies, and choice of therapy should be individualized.

Levetiracetam Sandoz injection should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period, it may be used, but it should be returned to refrigeration promptly.

The medication is given by intravenous infusion, typically over 15 minutes to 30 minutes, depending on the clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy, with appropriate monitoring of vital signs and seizure activity throughout the infusion.

Serious adverse reactions, although uncommon, include severe allergic responses such as anaphylaxis, mood disturbances like depression or suicidal thoughts, and hematologic abnormalities such as thrombocytopenia. Patients should be monitored for any new or worsening psychiatric symptoms, skin rash, or signs of infection, and medical attention should be sought immediately if they occur.

Levetiracetam injection is contraindicated in individuals with a known hypersensitivity to levetiracetam or any of the excipients in the formulation. Caution is also advised for patients with severe renal impairment, as dose adjustment may be required, and for those with a history of serious psychiatric disorders, where close monitoring is essential.